These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 17224219

  • 1. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.
    Vaccine; 2007 Mar 01; 25(11):1969-92. PubMed ID: 17224219
    [Abstract] [Full Text] [Related]

  • 2. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.
    Vaccine; 2007 Apr 12; 25(15):2863-85. PubMed ID: 17113200
    [Abstract] [Full Text] [Related]

  • 3. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M.
    Vaccine; 2009 May 21; 27(24):3165-74. PubMed ID: 19446187
    [Abstract] [Full Text] [Related]

  • 4. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28179536
    [Abstract] [Full Text] [Related]

  • 5. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.
    Virus Res; 2006 Mar 01; 116(1-2):11-20. PubMed ID: 16214252
    [Abstract] [Full Text] [Related]

  • 6. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE, Abaitua F, Rodríguez D, Esteban M.
    Virus Res; 2004 Sep 15; 105(1):11-22. PubMed ID: 15325077
    [Abstract] [Full Text] [Related]

  • 7. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M.
    J Virol; 2015 Aug 15; 89(16):8525-39. PubMed ID: 26041302
    [Abstract] [Full Text] [Related]

  • 8. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.
    J Virol; 2015 Jan 15; 89(2):970-88. PubMed ID: 25355891
    [Abstract] [Full Text] [Related]

  • 9. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V.
    Viral Immunol; 2005 Jan 15; 18(4):678-88. PubMed ID: 16359234
    [Abstract] [Full Text] [Related]

  • 10. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K, Xin KQ, Kojima Y, Saha S, Okuda K, Okuda K.
    Clin Immunol; 2006 Apr 15; 119(1):32-7. PubMed ID: 16458074
    [Abstract] [Full Text] [Related]

  • 11. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B, Sánchez-Corzo C, Sorzano COS, Saiz L, Mediavilla P, Esteban M, Gómez CE.
    Viruses; 2019 Feb 16; 11(2):. PubMed ID: 30781504
    [Abstract] [Full Text] [Related]

  • 12. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L, Anand KK, Mohankumar KM, Ranga U.
    J Virol; 2004 Sep 16; 78(17):9174-89. PubMed ID: 15308713
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.
    Vaccine; 2004 Sep 09; 22(27-28):3676-90. PubMed ID: 15315847
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D, Bolesta E, Naito T, Gzyl J, Kaneko Y, Kozbor D.
    J Hum Virol; 2001 Sep 09; 4(6):306-16. PubMed ID: 12082397
    [Abstract] [Full Text] [Related]

  • 16. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, Orbea HA, Pantaleo G, Wagner R, Esteban M, Kraehenbuhl JP, Sirard JC.
    Vaccine; 2004 Sep 03; 22(25-26):3395-403. PubMed ID: 15308364
    [Abstract] [Full Text] [Related]

  • 17. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
    Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.
    J Virol; 2011 Nov 03; 85(21):11468-78. PubMed ID: 21865377
    [Abstract] [Full Text] [Related]

  • 18. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 03; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 19. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B.
    Virology; 2002 Mar 15; 294(2):270-81. PubMed ID: 12009868
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ, Otten GR, Doe B, Liu H, Srivastava R, Greer C, Legg H, Tang T, Polo JM, Donnelly JJ, Ulmer JB, Barnett SW.
    Vaccine; 2006 Apr 05; 24(15):2755-63. PubMed ID: 16460840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.